Why Medpace Holdings, Inc. (MEDP) stock moved
Medpace Holdings, Inc. (MEDP) shares climbed 6.4% to $662.48 as of October 22, 2026, a significant gain from the prior close of $622.43. BestStocks flagged the session as a major change for MEDP. The move is tied to company news. Below, we break down what changed for MEDP, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
MEDP climbed 6.4% in its latest session, moving from $622.43 to $662.48.
What it means for Medpace Holdings, Inc. investors
For Medpace Holdings, Inc. investors, the balance of recent signals points to a strong bullish shift. On the constructive side: Earnings beat with positive market reaction; Strong 6.4% price move with conviction. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $620.44, implying -6.3% downside from $662.48. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 109 days out, the next report is the most likely near-term test of the move.
MEDP price reaction
MEDP last traded at $662.48, up $40.05 (+6.43%) from the previous close of $622.43. The session traded on 3.5× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $598.08 and $662.48, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Medpace Holdings, Inc. (MEDP)
The consensus analyst price target on Medpace Holdings, Inc. (MEDP) is $620.44, 6.3% below the recent $662.48. Over the past 90 days analysts logged 1 upgrade, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MEDP line up.
The bullish case
- The Street's most bullish target is $700.00 (+5.7%).
- 1 analyst upgrade in the past 90 days, most recently UBS to Neutral (2026-09-30).
- Earnings beat with positive market reaction.
- Strong 6.4% price move with conviction.
- Volume 3.5x average — institutional conviction.
The bearish case
- The consensus analyst price target of $620.44 sits 6.3% below the recent $662.48, so the average target sees limited room to run.
- The most bearish analyst target is $515.00 (-22.3%).
Weighing both sides, BestStocks' composite read of recent signals is strongly bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MEDP
In-depth MEDP event analyses
Frequently asked questions about MEDP
Why did Medpace Holdings, Inc. (MEDP) stock move?
MEDP climbed 6.4% to $662.48. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MEDP stock rise?
MEDP gained 6.43% ($40.05) versus the prior close of $622.43, last trading at $662.48 on 3.5× average volume.
When is Medpace Holdings, Inc.'s next earnings date?
MEDP's next earnings report is estimated for 2027-02-08 — about 109 days away.
What is the analyst price target for MEDP?
The consensus analyst price target for MEDP is $620.44, about 6.3% below the current $662.48. Over the past 90 days, analysts recorded 1 upgrade, 8 maintains, and 0 downgrades.
How BestStocks tracks MEDP
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for MEDP, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.